Trials / Completed
CompletedNCT02491606
Evaluation of Weekly Tafenoquine
Evaluation of Weekly Tafenoquine (SB 252263 / WR 238605) Compared to Placebo for Chemosuppression of Plasmodium Falciparum in Western Kenya
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 2b, placebo controlled, randomized, blinded study of the efficacy of WR 238605, a new primaquine analog, compared to placebo as chemosuppression of P. falciparum malaria in Nyanza Province, western Kenya.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafenoquine | Tafenoquine 200mg and 400 mg |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 1997-05-01
- Primary completion
- 1997-09-01
- Completion
- 1998-09-01
- First posted
- 2015-07-08
- Last updated
- 2018-09-13
Source: ClinicalTrials.gov record NCT02491606. Inclusion in this directory is not an endorsement.